These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10488324)

  • 1. [The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study].
    Schwinger RH
    Dtsch Med Wochenschr; 1999 Aug; 124(34-35):987-8. PubMed ID: 10488324
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anti-aldosterone therapy in severe heart failure].
    van Guldener C; Donker AJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1724-6. PubMed ID: 10494316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Randomized Aldactone Evaluation Study (RALES)].
    Uchida K; Nakano S; Kigoshi T
    Nihon Rinsho; 2005 Mar; 63 Suppl 3():330-5. PubMed ID: 15813090
    [No Abstract]   [Full Text] [Related]  

  • 4. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
    Masoudi FA; Gross CP; Wang Y; Rathore SS; Havranek EP; Foody JM; Krumholz HM
    Circulation; 2005 Jul; 112(1):39-47. PubMed ID: 15983243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of spironolactone in a specialized heart failure clinic.
    Sligl W; McAlister FA; Ezekowitz J; Armstrong PW
    Am J Cardiol; 2004 Aug; 94(4):443-7. PubMed ID: 15325926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spironolactone use in patients with heart failure.
    Trujillo JM; Gonyeau MJ; DiVall MV; Alexander SL
    J Clin Pharm Ther; 2004 Apr; 29(2):165-70. PubMed ID: 15068406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone antagonists in congestive heart failure.
    Soberman J; Chafin CC; Weber KT
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1024-8. PubMed ID: 12186262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
    Diercks GF; Overdiek JW; van Veldhuisen DJ
    Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The significance of aldosterone in chronic heart failure: the RALES study].
    Simko F; Bada V; Simková M; Simko J; Kovács L; Hulín I
    Vnitr Lek; 2002 Aug; 48(8):767-72. PubMed ID: 12425209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New evidence for the usefulness of an old drug in the treatment of heart failure].
    Oseguera Moguel J
    Rev Invest Clin; 2000; 52(1):14-6. PubMed ID: 10818804
    [No Abstract]   [Full Text] [Related]  

  • 11. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure.
    Masoudi FA; Havranek EP; Wolfe P; Gross CP; Rathore SS; Steiner JF; Ordin DL; Krumholz HM
    Am Heart J; 2003 Aug; 146(2):250-7. PubMed ID: 12891192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
    Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG
    Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of diuretics and aldosterone antagonists in the treatment of heart failure].
    Schwinger RH
    Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S40-7. PubMed ID: 10535046
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of spironolactone on C-reactive protein levels in patients with heart disease.
    Godfrey V; Farquharson CA; Macdonald JE; Yee KM; Struthers AD
    Int J Cardiol; 2007 Apr; 117(2):282-4. PubMed ID: 16899309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
    Ko DT; Juurlink DN; Mamdani MM; You JJ; Wang JT; Donovan LR; Tu JV
    J Card Fail; 2006 Apr; 12(3):205-10. PubMed ID: 16624686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
    Bansal S; Lindenfeld J; Schrier RW
    Circ Heart Fail; 2009 Jul; 2(4):370-6. PubMed ID: 19808361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS; Cruz LS; Domingues GS; Souza CA
    Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic heart insufficiency should be treated also with spironolactone].
    Kjeldsen KP; Nørgaard A; Thygesen K
    Ugeskr Laeger; 1999 Sep; 161(37):5132. PubMed ID: 10523942
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.